Astellas reports IZERVAY reduced driving eligibility loss risk in eye disease study
Go back to Astellas reports IZERVAY reduced driving eligibility loss risk in eye disease study| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 13.42 +0.16 (1.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.26 | 52 Week High | $19.40 | |||
| Open | $13.34 | 52 Week Low | $12.50 | |||
| Day High | $13.44 | P/E | N/A | |||
| Day Low | $13.30 | EPS | $0.00 | |||
| Volume | 164,997 | |||||
